About the role

Aplyr's Quick Take

This role is about leading the strategy for engaging healthcare professionals in a more integrated way, focusing on educational initiatives and field interactions. It's a senior-level position that involves coordinating various medical affairs activities and ensuring they align with the company's goals, particularly in rare diseases like Skeletal Dysplasia.

Good fit

Ideal candidates have extensive experience in medical affairs, particularly in biopharma, and a strong background in engaging healthcare professionals. They should be strategic thinkers who thrive in dynamic environments and are comfortable with both leadership and hands-on execution.

Worth noting

The role emphasizes innovation and a non-traditional approach to biopharma, which may appeal to those looking for a creative and impactful position. However, the focus on rare diseases may require specialized knowledge that not all candidates will possess.

Mavericks Wanted

When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on
 
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible. 
 
Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.

What you’ll do

As the Senior Director, Integrated HCP Engagement, you will define and lead a more coordinated and scalable approach to Medical Affairs engagement—connecting field-based interactions, educational initiatives, congress activity, and thoughtfully applied digital channels into a cohesive strategy.

A key focus of this role is to expand scientific exchange and build more tailored, accessible educational experiences for healthcare professionals, ensuring we meet HCPs where they are and support their evolving needs.

Initially focused on Skeletal Dysplasia (QED), with potential to support the Endocrinology Affiliate (Calcilytix), this role is critical to advancing late-stage development programs and strengthening launch readiness.

You will serve as a strategic partner to Medical leadership, working across HQ, Field Medical, and Scientific Communications to expand reach, deepen engagement, and ensure consistency and impact across all external interactions.

Key Responsibilities

Engagement Strategy & Capability Development

Define and lead a coordinated HCP engagement strategy that connects:
- Field Medical interactions
- Educational programming (live and virtual)
- Congress planning and follow-up engagement
Introduce and scale new approaches to scientific exchange, including:
- Broader use of virtual and asynchronous engagement
- More personalized delivery of educational content based on HCP needs and roles
Establish clear ways of working and alignment across teams to ensure consistent execution
Support the evolution from reactive engagement to a more intentional and strategic model

QED: Expand and Strengthen Scientific Exchange

Expand and diversify the external expert network beyond current core KOLs
Build relationships with emerging thought leaders and additional centers of excellence
Extend scientific exchange beyond traditional 1:1 interactions while maintaining depth and rigor
Strengthen i

Skills & Tags

react go ai ios data design

Aplyr's read

BridgeBio Pharma is a dynamic biotechnology firm dedicated to tackling genetic diseases and cancers, attracting professionals passionate about impactful medical advancements.
Synthesized from recent postings & public sources

What's promising

•BridgeBio focuses on innovative treatments for genetic diseases, offering significant potential for groundbreaking medical advancements.
•The company has a robust pipeline with multiple late-stage clinical trials, indicating strong future growth prospects.
•BridgeBio's strategic partnerships enhance its research capabilities and expand its therapeutic reach.

What to watch

•The company faces high financial risk due to significant R&D expenditures without guaranteed success.
•BridgeBio operates in a highly competitive market with numerous established players.
•Regulatory hurdles for drug approvals can delay product launches and impact revenue.

Why BridgeBio Pharma

•BridgeBio's focus on genetic diseases and cancers sets it apart in the biotechnology sector.
•The company's decentralized model allows for nimble and efficient project management.
•BridgeBio's commitment to rare diseases addresses unmet medical needs, differentiating its mission.

Aplyr’s read is generated by AI from public sources. Was it useful?